<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">ISHIKAWA, TAKASHI</style></author><author><style face="normal" font="default" size="100%">SHIMIZU, SATORU</style></author><author><style face="normal" font="default" size="100%">KATAYAMA, KIYOFUMI</style></author><author><style face="normal" font="default" size="100%">CHISHIMA, TAKASHI</style></author><author><style face="normal" font="default" size="100%">HAMAGUCHI, YOHEI</style></author><author><style face="normal" font="default" size="100%">DOI, TAKAKO</style></author><author><style face="normal" font="default" size="100%">TANABE, MIKIKO</style></author><author><style face="normal" font="default" size="100%">KASAHARA, AKIO</style></author><author><style face="normal" font="default" size="100%">YAMAGUCHI, NAOTAKA</style></author><author><style face="normal" font="default" size="100%">NARUI, KAZUTAKA</style></author><author><style face="normal" font="default" size="100%">OHTA, IKUKO</style></author><author><style face="normal" font="default" size="100%">MATSUMOTO, CHIZURU</style></author><author><style face="normal" font="default" size="100%">SHIMIZU, DAISUKE</style></author><author><style face="normal" font="default" size="100%">KITO, AYAKO</style></author><author><style face="normal" font="default" size="100%">SUDA, TAKASHI</style></author><author><style face="normal" font="default" size="100%">INABA, MASAAKI</style></author><author><style face="normal" font="default" size="100%">ASAGA, TARO</style></author><author><style face="normal" font="default" size="100%">MOMIYAMA, NOBUYOSHI</style></author><author><style face="normal" font="default" size="100%">ICHIKAWA, YASUSHI</style></author><author><style face="normal" font="default" size="100%">YOSHIMOTO, MASATAKA</style></author><author><style face="normal" font="default" size="100%">MORITA, SATOSHI</style></author><author><style face="normal" font="default" size="100%">SHIMADA, HIROSHI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1515-1520</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">The feasibility and efficacy of adriamycin or epirubicin in combination with cyclophosphamide followed by weekly paclitaxel (AC/EC-weekly PAC) as adjuvant chemotherapy for breast cancer was investigated. Patients and Methods: Node-positive breast cancer was treated with AC/ EC-weekly PAC, namely AC at 60/600 mg/m2 or EC at 90/600 mg/m2 ×4 at three-week intervals, followed by weekly PAC (80 mg/m2) ×12, namely four cycles of single weekly administration for three weeks followed by a one-week rest (3×4 PAC) or single weekly administration for 12 consecutive weeks (12 PAC). Results: One hundred and three of 109 consecutive patients enrolled were analyzed, of whom 96 (93.2%) completed the regimen. Grade 3/4 neutropenia occurred in 52.4% receiving AC/EC, and 10.9% of 55 receiving 12 PAC but only 2.1% of 48 receiving 3×4 PAC. Neuropathy disorders occurred in more than half receiving PAC, which did not improve after one-week rest in 3×4 PAC. Conclusion: AC/EC-weekly PAC is feasible and without serious complications.</style></abstract></record></records></xml>